Long Term Follow up for the Detection of Delayed Adverse Events in Cal-1 Recipients

Calimmune

Status: Active, not recruiting

Conditions: HIV-1 Infection; Receipt of Cal-1 Modified Hematopoietic Cellular Products

Treatments: Genetic: Blood tests

Study type: Observational

Funder types: Industry

Identifiers

NCT02390297

CAL-INT-00

Details and patient eligibility

About

Long term safety follow-up of Cal-1 recipients

Full description

Long Term Follow-up for the Detection of Delayed Adverse Events in Recipients of CD4+ T Lymphocytes and/or CD34+ Hematopoietic Stem/Progenitor Cells Transduced with LVsh5/C46 (Cal-1), a Dual Anti-HIV Gene Transfer Construct

Enrollment: 11 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Signed informed consent
• Previous treatment with the Cal-1 modified hematopoietic cellular products

Exclusion criteria

• Inability to understand and provide informed consent

Trial design

11 participants in 1 patient group

Single

Description:

Collection of blood samples for general health (complete blood count) and Cal-1 specific analyses

Treatment:

Genetic: Blood tests